merckwindow_web

MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes

pharmafile | October 15, 2018 | News story | Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma 

MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version of Sanofi’s Lantus (insulin glargine) for diabetes.

The deal, which was reached in February 2014 as an expansion of an existing agreement, concerned the development, manufacture and commercialisation of MK-1293, or Lusduna Nexvue. The pair was awarded a tentative approval from the FDA in July last year, but the development process was plagued with setbacks, foremost of which was patent infringement litigation levied by the originator manufacturer, Sanofi, delaying final approval by up to 30 months.

The decision was made after an assessment of the market, pricing, and production costs, deeming further development to be unfeasible. As a contingent of their parting ways, the companies confirmed that MSD had $155 million to Samsung Bioepis to cover its investments made under the partnership, plus interest.

A spokesperson for Samsung Bioepis said: “[MSD] decided to end the product development and commercialisation after reviewing the market environment and production costs.”

Advertisement

Despite their divergence on the project, the pair will continue to work together on its existing biosimilar collaborations in oncology and immunology, which remain unchanged.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Study to examine ways of improving diabetes care for younger adults

Researchers at Northumbria University are leading a £1.3m study aimed at helping GP practices improve …

The Gateway to Local Adoption Series

Latest content